レポートアーカイブ
すべてのリサーチ
52 ページ中 40 ページ · 全 1238 本
40/100
Pfizer: A Long-Term Business-Owner's Investment Research
Pfizer is a large-cap pharmaceutical company in a recovery phase: 2025 revenue of $62.58 billion and operating cash flow of $11.70 billion, with the core ex-COVID business up 6% and dividend coverage comfortable. The Vyndaqel patent settlement extends exclusivity to 2031, but the Seagen and Metsera capital-allocation bets have yet to prove out. Rating Watch: at $25.85, the stock sits near neutral intrinsic value, with a fair buy range of $18-21.
44/100
84Buffett
P&G Deep-Dive Value Research Report
A global consumer-staples leader whose five categories reach nearly 5 billion consumers, with textbook-quality financials and thick cash flows. At the current $144.44 the stock trades at a 21.1x P/E, and its owner-earnings yield of just 4.7% sits only marginally above the 10-year Treasury, leaving no visible margin of safety. Rating: Watch — a great business at a normal-to-slightly-rich price rather than an obviously cheap one.
45/100
Progressive: A Long-Term Owner's Perspective
A high-quality property-and-casualty compounding machine with strong underwriting discipline, dual-channel distribution, and high-quality float. At 2025's 87.4 combined ratio and roughly 3.64x PB / 10.15x PE, the market has already fully priced in a long continuation of high ROE, so it reads more like a good company than a good buy. Rating Watch: ideal entry $130-155.
45/100
78Buffett
Parker-Hannifin: A Long-Term Owner's Perspective
A platform-type industrial company in motion and control technology, with a fragmented customer base, hundreds of thousands of SKUs, strong cash flow, and low capex intensity. At a current P/E of 31.98x and a conservative owner-earnings yield of about 3.1% that already trails the Treasury yield, the price sits in the low-to-mid range of the optimistic scenario. Rating Watch: a good company at a full price, ideal buy $550-700.
43/100
Prologis: A Long-Term Owner's Perspective
The world's leading logistics real estate REIT: 1.3 billion square feet, $235 billion in AUM, 4.8x leverage, and 2025 AFFO of $4.335 billion. At the current price of $145.90 the stock already sits in the optimistic value band, with an owner earnings yield of just 3.0%, below the 10Y Treasury, leaving an insufficient margin of safety.
46/100
76Buffett
Philip Morris International: In-Depth Value Investment Research
Philip Morris International is a global nicotine company leading the shift to smoke-free products, with smoke-free products contributing 41.5% of 2025 net revenue. At the current price of USD 188.99, its conservative Owner Earnings yield is only 3.7%, below the 10-year U.S. Treasury yield, leaving no obvious margin of safety. Rating Watch: a high-quality compounder, but the current valuation already prices in much of the good news.
43/100
53Buffett
Quanta Services: A Long-Term Owner's Perspective
North America's leading grid and utility infrastructure contractor, benefiting from data centers, electricity load, and manufacturing reshoring; but at roughly 106x PE, 67x P/FCF, and 12x PB, the current price already discounts many years of high growth, a 90%-160% premium to fair value, with an ideal buy-in of $230-320.
44/100
38Buffett
RTX Corporation: A Long-Term Value Study
A global aerospace and defense giant spanning aviation parts/systems, commercial aero-engines, and missiles/air defense, with a Q1 2026 backlog of $271 billion. At $177.01 and a 33.2x P/E, it is a good business at a full-to-rich price: the GTF powdered-metal event is still clearing and the margin of safety is insufficient. Rating Watch: worth respecting, but better to wait for a pullback.
44/100
68Buffett
Charles Schwab: A Long-Term Owner's Perspective
A platform with $12 trillion in client assets and genuine cost advantages. At $86, however, the stock trades at only a slight discount to a relatively neutral intrinsic value, while net interest margin is sensitive to interest rates and client-cash migration. Margin of safety is thin; rating: Watch.
41/100
35Buffett
The Southern Company: A Long-Term Owner's Perspective
The Southeast's leading regulated utility, with 25 consecutive years of dividend increases; new Vogtle nuclear units entering rate base plus data-center load support mid-term growth, but 2026-2030 capital spending of $81 billion and heavy reliance on external financing, while the current PE of 20.8x and PB of 2.96x already embed a defensive-plus-growth premium, with an ideal buy at $60-72.
51/100
75Buffett
S&P Global: A Long-Term Owner's View
An institutionalized intangible-asset earnings machine, with 2025 free cash flow of 5.135 billion dollars and capex at just 1.3% of revenue. At the current price of 417.60 dollars, roughly 26.4x trailing PE, it sits in the middle of its fair-value band, leaving an inadequate margin of safety. Rating Watch: a superb compounder whose quality is already priced in, so buying here means paying for long-term quality rather than buying an obvious bargain.
40/100
Exxon Mobil Deep Value Analysis: A Good Asset, Not a Cheap One
XOM is a standout in the oil and gas industry: real through-cycle resilience, an advantaged Permian/Guyana/LNG asset portfolio, and a 43-year dividend growth streak all hold up; but at $154 a share the price already sits near the upper edge of the model's optimistic range, and the 4.2% conservative owner earnings yield can't even beat the 10-year Treasury.
47/100
Welltower: A Long-Term Owner's Perspective
Welltower is a senior housing and healthcare real estate platform positioned for aging-driven demand. The core issue is valuation: at $216.17 and roughly 34x P/NFFO, the market has already paid for an optimistic long-term scenario, while the failed 2026 say-on-pay vote warrants governance monitoring. Research rating Watch: a high-quality compounder worth following, but current pricing leaves limited margin of safety.
49/100
95Buffett
Visa Inc. Long-Term Business Owner Research
Visa is one of the world's strongest payment networks, with a 60% FY2025 operating margin and $21.5 billion of free cash flow. At the current price of $328.88, P/FCF is about 29x, leaving no obvious margin of safety. Report rating Watch: a rare-quality business that deserves long-term attention, but the current entry point looks more fair-to-slightly-expensive than clearly cheap.
43/100
77Buffett
Union Pacific: A Long-Term Owner's Perspective
An irreplaceable rail network spanning two-thirds of the western United States, of exceptionally high quality; but at $265.88 the stock already sits well above fair value, and with the added uncertainty of the Norfolk Southern acquisition, the offer looks aggressive. Rating: Watch.
43/100
84Buffett
UnitedHealth Group (UNH): A Deep-Dive Value Investing Study
The largest integrated health insurance and PBM platform in the U.S., recovering after a 41% drop in 2025 operating profit; at the current $388.47 the stock sits in the upper part of its fair-value range with no clear margin of safety. Rating: Watch.
50/100
33Buffett
Uber Technologies Deep Value Research
Uber is a global multi-sided platform with 202 million MAPCs and 13.567 billion trips, 2025 revenue of $52.017 billion, adjusted EBITDA of $8.73 billion, and an asset-light model that is now releasing real free cash flow. The core thesis is that Uber has become a better business, but a 6.2% FCF yield versus a 4.57% 10-year U.S. Treasury yield leaves limited risk compensation amid regulatory, AV, and M&A uncertainty. Report rating Watch: a high-quality platform that is better kept on a priority watchlist until the fair buy range of $50 to $60 offers a thicker margin of safety.
47/100
69Buffett
Thermo Fisher: A Long-Term Owner's Perspective
Thermo Fisher Scientific is a full-stack scientific infrastructure platform spanning instruments, consumables, services, CRO, and CDMO capabilities. At $448, with a static P/E of 24.6x and $65.2 billion of goodwill and acquisition-related intangibles, long-term returns depend heavily on acquisition quality and execution. Rating Watch: a high-quality business, but the current price does not offer a clearly sufficient margin of safety.
43/100
67Buffett
TJX: A Long-Term Owner's Perspective
The world's largest off-price discount retailer, with scale-driven sourcing and a negative cash conversion cycle. But at $158 its FCF yield is only 2.8%, and the margin of safety is clearly insufficient. Rating Watch: a good company whose current price already prices in its excellence.
51/100
61Buffett
ServiceNow: A Value Investing Study
The leading enterprise workflow operating-system platform (post-split share price $102.25), with strong subscription stickiness and high cash-flow quality, yet on a conservative Owner Earnings basis that treats stock-based compensation as a real cost, the roughly 41x multiple still looks tight; ideal buy range $70-85. Rating Watch: an excellent business, but at today's price you are buying the expectation of continued excellence rather than an obviously undervalued asset.
49/100
83Buffett
Stryker In-Depth Value Investment Research
Stryker is a global medical device platform leader with deep moats in orthopaedics, the Mako robotics platform, and neurovascular products. Cash flow continues to strengthen, but at roughly 36.6x PE, valuation is tight and the ideal buy range is $185-230. Research rating Watch: a high-quality compounder that deserves long-term attention, but the current price leaves limited margin of safety.
47/100
36Buffett
Howmet Aerospace Deep Value Investment Research
Howmet Aerospace is a high-quality leader in aero-engine components and fastening systems, with a deep moat and steadily expanding margins. The core thesis is that the business is strong, but the current PE of about 59.5x already prices in years of high growth, smooth M&A integration, and sustained premium valuation, leaving too little margin of safety. Research rating Watch: an excellent aerospace compounder, but the ideal entry range is $90-125 rather than today's price.
49/100
Medtronic Long-Term Value Investment Analysis
Medtronic is a global medical-device leader with diversified exposure across cardiovascular, neuroscience, surgical, and diabetes franchises. Its cash flow is resilient, but the current PE of about 22x sits near the upper end of a neutral valuation range, leaving too little margin of safety; adding exposure would be more attractive after a pullback to $60-65. Research rating Hold: a durable compounder, but current pricing limits expected return.
35/100
51WORLD: A Deep Research Report
A scarce Hong Kong-listed name on the digital-twin and physical-AI theme, with 2025 revenue of RMB 348 million and a gross margin that fell from 51.1% to 30.0%; at roughly 100x P/S, the price already discounts the optimistic scenario. 51Aes remains the engine of the income statement while the 51Sim growth leg has yet to monetize, putting a fair buy range at HK$35 to HK$50. Rating Watch: the technology and the theme are both scarce, but the current price has already priced in the bull case and needs 51Sim ramp and margin repair to be confirmed by the financials.